Associated tags: TSE, Cardiopulmonary bypass, Airline, Pharmaceutical industry, Hospital, Health care, Deryk Houston, Friends, Blood transfusion, Health, History, Patient, USD, Blood, Perfusion, International trade, Workforce, Terumo
Retrieved on:
Thursday, September 15, 2022
TSE,
Health,
Workforce,
International trade,
Perfusion,
Blood,
Company,
Growth,
Industry,
USD,
Patient,
History,
CEO,
Technology,
Blood transfusion,
Solution,
EMEA,
Cardiopulmonary bypass,
Friends,
Deryk Houston,
Health care,
Hospital,
Multimedia,
Pharmaceutical industry,
Airline,
Terumo CARTAGO, Costa Rica, Sept. 15, 2022 /PRNewswire/ -- Terumo Cardiovascular, a global leader in medical devices for cardiac and vascular surgery, marked the opening of its newest manufacturing plant in La Lima, Cartago, Costa Rica.
Key Points:
- CARTAGO, Costa Rica, Sept. 15, 2022 /PRNewswire/ -- Terumo Cardiovascular, a global leader in medical devices for cardiac and vascular surgery, marked the opening of its newest manufacturing plant in La Lima, Cartago, Costa Rica.
- The new facility is home to Terumo's Perfusion Circuit Technology and Manufacturing Center and welcomes the first company to produce this line of medical equipment in Costa Rica.
- DeRyke also highlighted the country's many advantages: "Costa Rica has a strong cultural alignment with Terumo Cardiovascular and the countries where we operate.
- As a result, Terumo Cardiovascular is investing US $42 million in a new Perfusion Circuit Technology and Manufacturing Center in Costa Rica, the first plant of the cardiovascular division in Latin America.
Retrieved on:
Thursday, September 9, 2021
Data Management,
Health,
Technology,
Software,
General Health,
Cardiology,
Etiometry,
Terumo Cardiovascular,
Terumo Corporation,
ETIOMETRY,
TERUMO CARDIOVASCULAR,
TERUMO CORPORATION The partnership will bring advanced clinical decision support to adult cardiac surgery patients during surgery and their post-surgery recovery.
Key Points:
- The partnership will bring advanced clinical decision support to adult cardiac surgery patients during surgery and their post-surgery recovery.
- The platform can automate and deploy Enhanced Recovery After Surgery (ERAS) protocols for the management of cardiac surgery patients throughout their hospital stay.
- The Etiometry data and analytics platform provides clinicians with insights that can help improve overall quality of care for cardiac surgery patients.
- Terumo Cardiovascular manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass and intra-operative monitoring.
CytoSorb previously received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for use in adult, critically-ill COVID-19 patients with imminent or confirmed respiratory failure.
Key Points:
- CytoSorb previously received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for use in adult, critically-ill COVID-19 patients with imminent or confirmed respiratory failure.
- Under the initial terms of the agreement, Terumo Cardiovascular will ensure hospitals in the defined hot-spot states have access to the CytoSorb therapy for use in critically-ill COVID-19 patients that meet strict criteria under CytoSorbents' EUA.
- These include its CAPIOX FX25 Oxygenator, CDI 550 Blood Parameter Monitoring System, and Terumo Advanced Perfusion 1 heart-lung machine.
- Robert DeRyke, President and CEO of Terumo Cardiovascular, commented, "We are excited to expand our collaboration with CytoSorbents to the United States.
